Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immuno...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/11/2/171 |
| _version_ | 1827653374356488192 |
|---|---|
| author | Caiqin Hu Dan Li Zhanmou Liu Li Ren Junwei Su Meiling Zhu Yi Feng Zheng Wang Qiang Liu Biao Zhu Yiming Shao |
| author_facet | Caiqin Hu Dan Li Zhanmou Liu Li Ren Junwei Su Meiling Zhu Yi Feng Zheng Wang Qiang Liu Biao Zhu Yiming Shao |
| author_sort | Caiqin Hu |
| collection | DOAJ |
| description | Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research. |
| first_indexed | 2024-03-09T21:17:00Z |
| format | Article |
| id | doaj.art-7d92c44f62a64ba4b94caf5b9641db40 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-09T21:17:00Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-7d92c44f62a64ba4b94caf5b9641db402023-11-23T21:31:29ZengMDPI AGPathogens2076-08172022-01-0111217110.3390/pathogens11020171Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated PopulationsCaiqin Hu0Dan Li1Zhanmou Liu2Li Ren3Junwei Su4Meiling Zhu5Yi Feng6Zheng Wang7Qiang Liu8Biao Zhu9Yiming Shao10State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaState Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning 530021, ChinaState Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaState Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaState Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaState Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaGobond Testing Technology (Beijing) Co., Ltd., Beijing 102629, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaAssessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research.https://www.mdpi.com/2076-0817/11/2/171SARS-CoV-2neutralizing antibodies (nAbs)binding antibodiesconvalescent patients (CP)BBIBP-CorV vaccination |
| spellingShingle | Caiqin Hu Dan Li Zhanmou Liu Li Ren Junwei Su Meiling Zhu Yi Feng Zheng Wang Qiang Liu Biao Zhu Yiming Shao Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations Pathogens SARS-CoV-2 neutralizing antibodies (nAbs) binding antibodies convalescent patients (CP) BBIBP-CorV vaccination |
| title | Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations |
| title_full | Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations |
| title_fullStr | Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations |
| title_full_unstemmed | Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations |
| title_short | Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations |
| title_sort | exploring rapid and effective screening methods for anti sars cov 2 neutralizing antibodies in covid 19 convalescent patients and longitudinal vaccinated populations |
| topic | SARS-CoV-2 neutralizing antibodies (nAbs) binding antibodies convalescent patients (CP) BBIBP-CorV vaccination |
| url | https://www.mdpi.com/2076-0817/11/2/171 |
| work_keys_str_mv | AT caiqinhu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT danli exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT zhanmouliu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT liren exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT junweisu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT meilingzhu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT yifeng exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT zhengwang exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT qiangliu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT biaozhu exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations AT yimingshao exploringrapidandeffectivescreeningmethodsforantisarscov2neutralizingantibodiesincovid19convalescentpatientsandlongitudinalvaccinatedpopulations |